Understanding What Cannot Be Seen
Reproductive medicine has always involved questions that cannot be answered by ultrasound examinations, hormone tests, or the visual assessment of an embryo alone. Some of the most important factors affecting reproduction are carried within chromosomes and genes—biological information that is invisible to the human eye.
As genetic science developed, it created new possibilities for understanding infertility, recurrent pregnancy loss, inherited disorders, and embryo development. It also introduced difficult medical and ethical questions that required careful interpretation.
At Jinemed, reproductive genetics has evolved as part of a multidisciplinary approach in which fertility physicians, embryologists, genetic specialists, laboratory teams, and patients work together. The objective is not to use genetic testing in every case, but to determine when it may provide meaningful information and how that information should guide responsible clinical decisions.
From Observation to Genetic Information
During the early decades of IVF, embryo selection was based primarily on development observed inside the embryology laboratory. Embryologists evaluated fertilisation, cell division, symmetry, fragmentation, and progression toward the blastocyst stage.
These observations remain valuable, but morphology cannot reveal everything about an embryo. An embryo may appear to develop normally while carrying a chromosomal abnormality. Similarly, a family may carry a specific genetic variant even when both parents are healthy and have no visible symptoms.
The development of reproductive genetics added a new layer of information to IVF. It allowed selected patients to investigate specific chromosomal or inherited risks before embryo transfer, while also helping clinical teams understand that genetic results must always be interpreted within the wider medical picture.
For Jinemed, the integration of genetics reflected the same principle that shaped the development of embryology and ICSI: new technology has value only when it answers a genuine clinical question.
The Role of Genetic Counselling
Genetic testing begins before the laboratory analysis itself. It begins with understanding the patient’s history.
A detailed evaluation may include:
- Known genetic conditions within the family
- Previous pregnancies affected by an inherited disorder
- Recurrent miscarriages
- Chromosomal rearrangements identified in one of the partners
- A child or close relative with a genetic diagnosis
- Carrier screening results
- Previous IVF or genetic testing outcomes
Genetic counselling helps patients understand what a test can investigate, what it cannot exclude, what samples may be required, and how different possible results could affect treatment decisions.
This step is particularly important because reproductive genetics is not a single standard test. The appropriate method depends on the specific clinical question. A couple at risk of transmitting a known single-gene disorder requires a different pathway from a patient considering chromosomal screening of embryos.
Clear counselling allows patients to make informed decisions without presenting complex technology as a guarantee.
PGT-A: Evaluating Chromosome Number
Preimplantation Genetic Testing for Aneuploidy, or PGT-A, evaluates embryo samples for abnormalities in chromosome number.
Human embryos normally contain 46 chromosomes. When an embryo has an additional or missing chromosome, this is known as aneuploidy. Such abnormalities may prevent implantation, contribute to miscarriage, or in some cases result in an affected pregnancy.
PGT-A may be discussed in selected circumstances, depending on factors such as maternal age, reproductive history, previous IVF outcomes, the number of available embryos, and the couple’s individual priorities.
However, PGT-A is not automatically necessary for every IVF patient. It does not improve the biological quality of an embryo and cannot create normal embryos where none exist. It provides information that may help the medical team and patient decide which embryo to consider for transfer.
The potential value, limitations, cost, embryo numbers, and possibility of uncertain or mosaic findings should therefore be discussed before testing is planned.
PGT-M: Testing for a Specific Inherited Condition
Preimplantation Genetic Testing for Monogenic Disorders, or PGT-M, is designed for families with a known risk of transmitting a particular single-gene condition.
Unlike general chromosome screening, PGT-M is highly individualised. The genetic laboratory must know the relevant gene and variant, review the family’s diagnostic records, and often develop a case-specific testing strategy before the IVF cycle proceeds.
Depending on the condition and inheritance pattern, blood or DNA samples may be required from the couple, an affected child, or other family members. This preparation can take time because the purpose is to create a reliable method for distinguishing embryos that are affected, unaffected, or carriers when carrier status is relevant to the condition.
PGT-M can offer an important reproductive option to families affected by serious inherited diseases. Yet it remains a complex process. Not every genetic condition or family structure allows the same testing approach, and patients must understand the technical limitations before beginning treatment.
Structural Chromosomal Rearrangements
Some individuals carry a balanced chromosomal rearrangement without having any health problems themselves. However, the arrangement may lead to embryos with missing or additional chromosomal material, increasing the risk of implantation failure, miscarriage, or an affected pregnancy.
Preimplantation Genetic Testing for Structural Rearrangements, known as PGT-SR, may be considered when a translocation, inversion, or another relevant structural chromosome finding has been identified.
As with PGT-M, the process requires careful review of the couple’s genetic reports and coordination between the genetic and IVF teams. The exact expectations depend on the type of rearrangement and the number of embryos available for analysis.
Embryo Biopsy: Where Embryology Meets Genetics
Preimplantation genetic testing depends on close cooperation between two specialised laboratories.
First, embryos are created and cultured within the embryology laboratory. If an embryo reaches the appropriate blastocyst stage and is considered suitable for biopsy, an experienced embryologist carefully removes a small number of cells from the trophectoderm—the part of the blastocyst that later contributes to the placenta.
The biopsied cells are prepared and sent to the genetic laboratory for analysis. The embryo itself is usually vitrified and stored while the results are awaited.
This process requires precise identification, documentation, sample handling, communication, and quality control. A genetic result is meaningful only when every step—from patient identity and embryo culture to biopsy, transport, analysis, and reporting—has been managed correctly.
The connection between embryology and genetics is therefore not merely technical. It represents a chain of shared responsibility.
Interpreting Results Responsibly
Genetic results do not always fit into simple categories.
Depending on the test and laboratory findings, an embryo may be reported as chromosomally normal, abnormal, mosaic, affected, unaffected, a carrier, or inconclusive. Each description has a specific meaning and may require further discussion.
An inconclusive result does not necessarily mean that the embryo is abnormal. A mosaic result requires careful interpretation because the sampled cells may contain a mixture of findings, and professional recommendations can depend on the chromosomes involved, the degree of mosaicism, the patient’s circumstances, and the availability of other embryos.
For this reason, results should not be reduced to labels such as “good” or “bad.” They must be reviewed by qualified professionals and explained in language the patient can understand.
Even after preimplantation genetic testing, no result can guarantee implantation, pregnancy, or the birth of a child without any medical condition. Prenatal testing or diagnosis may still be discussed during pregnancy because PGT examines a limited sample of cells and cannot evaluate every possible genetic or developmental condition.
Ethics at the Centre of Genetic Care
Reproductive genetics carries responsibilities that extend beyond technology.
Testing decisions may affect not only the couple but also their children and extended family. Results can reveal unexpected carrier status, previously unknown family risks, or choices that are emotionally difficult.
At Jinemed, the ethical use of reproductive genetics is connected to several principles:
- Testing should have a clear medical purpose.
- Patients should receive understandable information before giving consent.
- Limitations and uncertain results should be discussed openly.
- Genetic information should be handled with confidentiality.
- No procedure should be presented as a guarantee.
- Patient decisions should be respected within medical, ethical, and legal boundaries.
These principles reflect Jinemed’s broader philosophy that scientific progress must remain connected to human dignity and responsible patient care.
International Patients and Complex Genetic Cases
Genetic cases often require more preparation than a standard IVF cycle, particularly for international patients.
Medical reports may need to be translated and reviewed. The exact genetic variant must be documented. Blood samples from relatives may be required. A specialised laboratory may need several weeks to design and validate a PGT-M test. Embryos may need to be frozen while testing is completed, followed by a later visit for frozen embryo transfer if a suitable embryo is identified.
Coordinating these stages requires clear communication between the patient, IVF team, genetics laboratory, and international patient coordinators.
Through its experience with patients from different countries, Jinemed and IVF Turkey have developed an understanding that complex genetic treatment cannot be organised as a simple travel package. Each family requires an individual medical pathway, realistic timing, and written explanations of the clinical and laboratory stages.
The Future of Reproductive Genetics
Genetic science continues to advance rapidly. Improved sequencing technologies, expanded carrier screening, more detailed embryo analysis, and the growing use of bioinformatics are creating new forms of information.
These developments may help medicine understand reproductive risk with greater precision. At the same time, more information does not always produce simpler decisions. New findings may be uncertain, difficult to interpret, or unrelated to the original reason for testing.
The future of reproductive genetics will therefore depend not only on what laboratories can detect, but also on how medical teams decide what should be tested, how evidence is evaluated, and how results are communicated responsibly.
Knowledge in the Service of Families
Reproductive genetics represents one of the clearest examples of Jinemed’s multidisciplinary philosophy. Physicians define the clinical question. Genetic specialists evaluate inheritance and testing strategy. Embryologists culture and biopsy embryos. Laboratories analyse the samples. Coordinators help patients understand the sequence of treatment.
Every part of the process is connected.
The purpose is not to pursue technology for its own sake. It is to give selected families information that may help them make informed reproductive decisions while preserving scientific honesty, ethical responsibility, and respect for the limits of medicine.
As genetic science continues to evolve, these principles will remain central to Jinemed’s approach.